

## Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

## Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal

Feb 20 2026, 7:25 AM EST

## Kane Biotech Expands Commercial Activities in the United States

Feb 19 2026, 7:25 AM EST

## Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser

Feb 17 2026, 7:25 AM EST

## Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	6.65m
Last Price	\$0.04
52-Week	\$0.025 - \$0.115

02/25/2026 08:02 PM EST

## Investor Relations

Kane Biotech Inc.  
T: 204-453-1301  
ir@kanebiotech.com

## Board of Directors

### Philip Renaud

Board Chair

### Dr. John Coleman

Director

### Anne Greven

Director

### Dr. Robert Huizinga

Interim Chief Executive Officer

### Dr. David Kideckel

Director

### Shameze Rampertab

Director

## Kane Biotech Inc.

190-100 Innovation Drive  
Winnipeg, MB R3T 6G2  
Canada

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.